You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens

  • Authors: Jeffrey S. Weber, MD, PhD; Charles G. Drake, MD, PhD; Jason J. Luke, MD
  • CME / ABIM MOC Released: 12/19/2018
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 12/19/2019, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, dermatologists, and other healthcare professionals who manage patients with cancer.

The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • The use of combination regimens with multiple mechanisms of action as strategies for treating cancer
    • The association between combination therapy and immune-related adverse events that may be associated with use of emerging cancer immunotherapy strategies


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Jeffrey S. Weber, MD, PhD

    Professor of Medicine
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, NY

    Disclosures

    Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
    Owns stock, stock options, or bonds from: Altor BioScience Corp.; Biond Biologics Ltd; CytoMX Therapeutics
    Other: Named on a patent for a PD-1 biomarker by Biodesix, Inc.

Panelists

  • Charles G. Drake, MD, PhD

    Professor of Oncology
    Cancer Immunotherapy Program
    Columbia University Medical Center
    New York, New York

    Disclosures

    Disclosure: Charles G. Drake, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Agenus Inc.; Dendreon Corporation; Janssen Pharmaceuticals; Lilly; MedImmune Inc.;Merck & Co., Inc.; Pierre Fabre; Roche
    Received grants for clinical research from: Aduro Biotech; Bristol-Myers Squibb Company; Janssen Pharmaceuticals
    Owns stock, stock options, or bonds from: Compugen Ltd.; Harpoon Therapeutics; Kleo Pharmaceuticals Inc.; Potenza Therapeutics; Tizona Therapeutics

  • Jason J. Luke, MD

    Assistant Professor of Medicine
    University of Chicago
    Chicago, Illinois

    Disclosures

    Disclosure: Jason J. Luke, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: 7 Hills Pharma LLC; Actym Therapeutics, Inc.; Aduro Biotech; Alphamab Co. Ltd; Array BioPharma; AstraZeneca Pharmaceuticals LP; Benevir Biopharm Inc.; Bristol-Myers Squibb Company; Castle Creek Pharma; Checkmate Pharmaceuticals; Compugen Ltd.; EMD Serono, Inc.; IDEAYA Biosciences; Janssen Pharmaceuticals; Mavupharma; Merck & Co., Inc.; NewLink Genetics Corporation; Novartis Pharmaceuticals Corporation; Reflexion Pharmaceuticals, Inc.; Spring Bank Pharmaceuticals; Syndax Pharmaceuticals, Inc.; Tempest Therapeutics Inc.; Vividion Therapeutics; WntRx Pharmaceuticals Inc
    Received grants for clinical research from: AbbVie Inc.; Array BioPharma; Boston Biomedical; Bristol-Myers Squibb Company; Celldex Therapeutics, Inc.; Checkmate Pharmaceuticals; Compugen Ltd.; Corvus Pharmaceuticals; Delcath Systems Inc.; EMD Serono, Inc.; Evelo Biosciences, Inc.; FivePrime Therapeutics; Genentech, Inc.; Immunocore; Incyte Corporation; Leap Therapeutics, Inc.; MacroGenics, Inc.; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Palleon Pharmaceuticals; Pharmacyclics, Inc.; TESARO, Inc.; Xencor, Inc.
    Other: Received reimbursement for travel from: Amgen Inc.; Array BioPharma; AstraZeneca Pharmaceuticals LP; Benevir Biopharm Inc.; Bristol-Myers Squibb Company; Castle Creek Pharma; Checkmate Pharmaceuticals; EMD Serono, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; NewLink Genetics Corporation; Novartis Pharmaceuticals Corporation; Reflexion Pharmaceuticals, Inc.

Steering Committee

  • Jeffrey S. Weber, MD, PhD

    As Above

  • Robert L. Ferris, MD, PhD

    Professor and Chief
    Division of Head and Neck Surgery
    Departments of Otolaryngology, Radiation Oncology, and Immunology
    Co-Leader
    Cancer Immunology Program
    University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania

    Disclosures

    Disclosure: Robert L. Ferris, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Benitec Bipharma Ltd; Bristol-Myers Squibb Company; EMD Serono, Inc.; Lilly; Merck & Co., Inc.; Pfizer Inc.; PPD; TESARO, Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; MedImmune Inc.; Merck & Co., Inc.; TESARO, Inc.; VentiRx

  • Ramaswamy Govindan, MD

    Professor of Medicine
    Division of Medical Oncology
    Washington University School of Medicine
    Co-Director
    Section of Medical Oncology
    Siteman Cancer Center
    Barnes-Jewish Hospital
    St Louis, Missouri

    Disclosures

    Disclosure: Ramaswamy Govindan, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adaptimmune; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; NeoHealth

  • Dung Le, MD

    Associate Professor
    Johns Hopkins University School of Medicine
    Baltimore, Maryland
    Participation by Dr Le does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Disclosures

    Disclosure: Dung Le, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck & Co., Inc.
    Served as a speaker or a member of a speakers bureau for: Merck & Co., Inc.
    Received grants for clinical research from: Aduro Biotech; Bristol-Myers Squibb Company; Merck & Co., Inc.

  • Brian I. Rini, MD

    Professor of Medicine
    Lerner College of Medicine
    Director
    GU Program
    Cleveland Clinic
    Cleveland, Ohio

    Disclosures

    Disclosure: Brian I. Rini, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Merck & Co., Inc.; Pfizer Inc.
    Received grants for clinical research from: Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc.

  • Jared Weiss, MD

    Assistant Professor of Medicine
    Lineberger Comprehensive Cancer Center
    University of North Carolina at Chapel Hill

    Disclosures

    Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Celgene Corporation; EMD Serono, Inc.; G1 Therapeutics; Immunicum; Nanobiotx; Regeneron Pharmaceuticals, Inc.
    Received grants for clinical research from: Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.

Editor

  • Charlotte Warren

    Senior Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

SITC Course Director

  • Shilpa Gupta, MD

    Associate Professor of Medicine
    Hematology Oncology and Transplantation
    University of Minnesota
    Minneapolis, Minnesota

    Disclosures

    Disclosure: Shilpa Gupta, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ARMO Biosciences; Exelixis, Inc; Janssen Pharmaceuticals
    Served as a speaker or a member of a speakers bureau for: Exelixis, Inc; Janssen Pharmaceuticals
    Received grants for clinical research from: Astellas Pharma; Bristol-Myers Squibb Company; Seattle Genetics, Inc.
    Owns stock, stock options, or bonds from: Nektar Therapeutics

SITC

  • Claire Leischer, MS

    Senior Manager of Online Education
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Claire Leischer, MS, has disclosed no relevant financial relationships.

  • Alicia Schuessler, CAE

    Director of Education
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Alicia Schuessler, CAE, has disclosed no relevant financial relationships.

  • Tara Withington, CAE

    Executive Director
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Tara Withington has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

SITC

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Society for Immunotherapy of Cancer. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens

Authors: Jeffrey S. Weber, MD, PhD; Charles G. Drake, MD, PhD; Jason J. Luke, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/19/2018

Valid for credit through: 12/19/2019, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print